Dr. Vogel to Lead Joint Breast Cancer Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly established joint breast cancer program of the University of Pittsburgh Cancer Institute and Magee-Womens Hospital. He will also join the University of Pittsburgh as professor of medicine and epidemiology.

PITTSBURGH--Victor Vogel, MD, MHS, will lead a newly establishedjoint breast cancer program of the University of Pittsburgh CancerInstitute and Magee-Womens Hospital. He will also join the Universityof Pittsburgh as professor of medicine and epidemiology.

Dr. Vogel comes to Pittsburgh from the University of Texas M.D.Anderson Cancer Center, where he was responsible for recruitingthe largest number of women onto the Breast Cancer PreventionTrial, the national study designed to determine the value of tamoxifen(Nolva-dex) in preventing breast cancer in high-risk women.

"One of the program's most important missions," Dr.Vogel said, "will be to enhance delivery of care to womenwho face barriers, ie, older women or those who are poor or livein rural areas."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.